APA Citation

(2008). Follow-on biologics: Hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007. Washington: U.S. G.P.O..

Chicago Style Citation

Follow-on Biologics: Hearing of the Committee On Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, First Session, On Examining Food and Drug Administration Follow-on Biologics, Generally Referred to As a Biotechnology-derived Protein Drug (or Biologic) That Is Comparable to a Novel, Previously Approved Biologic and That Is Approved With Less Supporting Data Than the Innovator Biologic, March 8, 2007. Washington: U.S. G.P.O., 2008.

MLA Citation

Follow-on Biologics: Hearing of the Committee On Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, First Session, On Examining Food and Drug Administration Follow-on Biologics, Generally Referred to As a Biotechnology-derived Protein Drug (or Biologic) That Is Comparable to a Novel, Previously Approved Biologic and That Is Approved With Less Supporting Data Than the Innovator Biologic, March 8, 2007. Washington: U.S. G.P.O., 2008.

Warning: These citations may not always be 100% accurate.